Press Releases

Press Release: Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery

Agreement includes upfront payment of $20 million with the potential for $1 billion in milestone-based payments plus tiered royalties SAN FRANCISCO — August 17, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will […]

Press Release: Atomwise Announces Nomination of its First AI-Driven Development Candidate Focused on TYK2 Inhibition and Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer
Atomwise Announces Nomination of its First AI-Driven Development Candidate Focused on TYK2 Inhibition and Appoints Neely Mozaffarian, MD, PhD as Chief Medical Officer

SAN FRANCISCO–(BUSINESS WIRE)– Atomwise, a leader in using AI for small molecule drug discovery, today announced the nomination of its first AI-driven development candidate focused on TYK2 inhibition and the appointment of Neely Mozaffarian, MD, PhD as Chief Medical Officer. Dr. Mozaffarian brings over 25 years of immunology and clinical research experience to the role […]


October 5, 2023

Atomwise Appoints Gavin Hirst, Ph.D., as Chief Scientific Officer
Atomwise Appoints Gavin Hirst, Ph.D., as Chief Scientific Officer

Veteran drug hunter adds discovery expertise to technology-enabled biopharma company SAN FRANCISCO, Calif. — September 14, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer. Dr. Hirst brings more than 30 years of expertise in drug discovery […]


September 14, 2022

Press Release: Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery

Agreement includes upfront payment of $20 million with the potential for $1 billion in milestone-based payments plus tiered royalties SAN FRANCISCO — August 17, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will […]

Leadership team additions
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]


January 25, 2022

JP Morgan Health Care Conference banner
Atomwise Invited to Present at the 2022 J.P. Morgan Healthcare Conference

Leading AI-pharma company among select few private companies to participate San Francisco, CA – January 5, 2022 – Atomwise, a technology-enabled pharmaceutical company leveraging the power of artificial intelligence (AI) to revolutionize small molecule drug discovery, today announced that it has been invited to present next week at the 40th Annual J.P. Morgan Healthcare Conference. […]


January 5, 2022
Atomwise SAB, BOD 2021
Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board

Experts include Mike Varney, Bruce Roth, John Hamer, Kemal Malik, and Andrew Lo SAN FRANCISCO, Calif., June 17, 2021 – Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on […]


June 17, 2021